Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting RAS-RAF Pathway, Enhancing Antitumor Activity and Overcoming Multidrug Resistance.
Inhibiting/disturbing the RAS-RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such pathway as the target, nine styrylbenzylsulfone derivatives generated from the platinum-based modification of the side chain of Rigosertib were designed. Among them, compound 29 showed the most potent antitumor activity in vitro with IC50 values at nanomolar level against the tested tumor cell lines and 1000-fold higher than cisplatin against the multidrug resistant cells (A549/CDDP, A549/DOX, and SKOV-3/CDDP cells) while showed only moderate cytotoxicity against normal cells (HEUVC cells). Compound 29 could clearly disturb signaling transduction between RAS and CRAF by directly bonding to CRAF and inhibit CRAF activation. Besides, the enhanced intracellular platinum level made 29 more potent than cisplatin in DNA damage, ROS accumulation and mitochondrial membrane potential decrease. Moreover, 29 induced apoptosis by endogenous pathway and efficiently inhibited tumor growth in A549 xenograft model without side effect.